Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment
Daxor (Nasdaq: DXR) announces a breakthrough study published in JACC: Case Reports revealing a distinct heart failure phenotype through their blood volume analysis (BVA) technology. The research, examining 179 advanced heart failure patients, identified that 20% (36 patients) exhibited a specific hypervolemia/polycythemia phenotype characterized by expanded blood volume overload and elevated red blood cells.
The condition potentially affects 700,000-1,400,000 US heart failure patients, representing 10-20% of ambulatory cases. Four patients received therapeutic phlebotomy treatment guided by BVA, resulting in significant symptom improvement with zero hospitalizations or deaths over a 12-month monitoring period. The study highlights that patients with this phenotype typically show worse clinical outcomes and face higher stroke and blood clot risks if untreated.
Daxor (Nasdaq: DXR) annuncia uno studio innovativo pubblicato su JACC: Case Reports che rivela un fenotipo di insufficienza cardiaca distinto attraverso la loro tecnologia di analisi del volume ematico (BVA). La ricerca, che ha esaminato 179 pazienti con insufficienza cardiaca avanzata, ha identificato che il 20% (36 pazienti) presentava un fenotipo specifico di ipervolemia/poliglobulia caratterizzato da un sovraccarico di volume ematico espanso e un numero elevato di globuli rossi.
Questa condizione potrebbe interessare 700.000-1.400.000 pazienti statunitensi con insufficienza cardiaca, rappresentando il 10-20% dei casi ambulatoriali. Quattro pazienti hanno ricevuto un trattamento terapeutico di flebotomia guidato dalla BVA, con un significativo miglioramento dei sintomi e zero ospedalizzazioni o decessi durante un periodo di monitoraggio di 12 mesi. Lo studio evidenzia che i pazienti con questo fenotipo mostrano tipicamente esiti clinici peggiori e affrontano un rischio maggiore di ictus e trombosi se non trattati.
Daxor (Nasdaq: DXR) anuncia un estudio innovador publicado en JACC: Case Reports que revela un fenotipo de insuficiencia cardíaca distinto a través de su tecnología de análisis de volumen sanguíneo (BVA). La investigación, que examinó a 179 pacientes con insuficiencia cardíaca avanzada, identificó que el 20% (36 pacientes) presentaba un fenotipo específico de hipervolemia/poliglobulia caracterizado por una sobrecarga de volumen sanguíneo ampliado y un número elevado de glóbulos rojos.
Esta condición podría afectar a 700,000-1,400,000 pacientes estadounidenses con insuficiencia cardíaca, representando el 10-20% de los casos ambulatorios. Cuatro pacientes recibieron tratamiento de flebotomía terapéutica guiada por BVA, lo que resultó en una mejora significativa de los síntomas sin hospitalizaciones ni muertes durante un período de monitoreo de 12 meses. El estudio destaca que los pacientes con este fenotipo suelen mostrar peores resultados clínicos y enfrentan un mayor riesgo de accidente cerebrovascular y coágulos sanguíneos si no son tratados.
Daxor (Nasdaq: DXR)는 혈액량 분석(BVA) 기술을 통해 독특한 심부전 표현형을 드러내는 혁신적인 연구를 JACC: Case Reports에 발표했습니다. 179명의 심부전 환자를 조사한 이 연구는 20% (36명)이 혈액량 과다와 적혈구 증가로 특징지어지는 특정한 고혈압/다혈증 표현형을 보였음을 확인했습니다.
이 상태는 700,000-1,400,000명의 미국 심부전 환자에게 영향을 미칠 수 있으며, 이는 외래 환자의 10-20%를 차지합니다. 4명의 환자가 BVA에 의해 안내된 치료적 정맥혈 제거를 받았으며, 12개월 모니터링 기간 동안 병원에 입원하거나 사망하지 않고 증상이 크게 개선되었습니다. 연구는 이 표현형을 가진 환자들이 일반적으로 더 나쁜 임상 결과를 보이며 치료받지 않을 경우 뇌졸중 및 혈전 위험이 더 높다는 것을 강조합니다.
Daxor (Nasdaq: DXR) annonce une étude révolutionnaire publiée dans JACC: Case Reports révélant un phénotype d'insuffisance cardiaque distinct grâce à leur technologie d'analyse du volume sanguin (BVA). La recherche, examinant 179 patients atteints d'insuffisance cardiaque avancée, a identifié que 20% (36 patients) présentaient un phénotype spécifique d'hypervolémie/polycythémie caractérisé par un excès de volume sanguin et un nombre élevé de globules rouges.
Cette condition pourrait toucher 700 000 à 1 400 000 patients américains atteints d'insuffisance cardiaque, représentant 10 à 20 % des cas ambulatoires. Quatre patients ont reçu un traitement par phlébotomie thérapeutique guidé par la BVA, entraînant une amélioration significative des symptômes sans hospitalisations ni décès durant une période de suivi de 12 mois. L'étude souligne que les patients présentant ce phénotype affichent généralement de moins bons résultats cliniques et font face à un risque accru d'accidents vasculaires cérébraux et de caillots sanguins s'ils ne sont pas traités.
Daxor (Nasdaq: DXR) kündigt eine bahnbrechende Studie an, die in JACC: Case Reports veröffentlicht wurde und einen spezifischen Herzinsuffizienz-Phänotyp durch ihre Technologie zur Analyse des Blutvolumens (BVA) offenbart. Die Forschung, die 179 Patienten mit fortgeschrittener Herzinsuffizienz untersuchte, stellte fest, dass 20% (36 Patienten) einen spezifischen Phänotyp von Hypervolämie/Polyglobulie aufwiesen, der durch ein erweitertes Blutvolumen und erhöhte rote Blutkörperchen gekennzeichnet ist.
Die Erkrankung könnte 700.000-1.400.000 US-Patienten mit Herzinsuffizienz betreffen, was 10-20% der ambulanten Fälle entspricht. Vier Patienten erhielten eine therapeutische Blutabnahme, die von BVA geleitet wurde, was zu einer signifikanten Verbesserung der Symptome ohne Krankenhausaufenthalte oder Todesfälle über einen Zeitraum von 12 Monaten führte. Die Studie hebt hervor, dass Patienten mit diesem Phänotyp typischerweise schlechtere klinische Ergebnisse zeigen und ein höheres Risiko für Schlaganfälle und Blutgerinnsel haben, wenn sie nicht behandelt werden.
- Identified new treatment opportunity in 20% of heart failure patients
- Zero hospitalizations/deaths in treated patients over 12-month period
- Large addressable market of 700,000-1,400,000 US patients
- Clinical validation through JACC publication
- Demonstrated superior diagnostic capability compared to standard blood tests
- None.
Insights
This groundbreaking research represents a significant advancement in heart failure management and strengthens Daxor's market position in diagnostic technology. The discovery that 20% of advanced heart failure patients have a previously unrecognized blood volume condition creates substantial market opportunities:
The identification of this specific phenotype in 700,000-1,400,000 US patients represents a significant expansion of Daxor's addressable market. This discovery is particularly valuable because:
- It identifies a previously undetected condition that standard blood tests miss, creating a compelling case for BVA adoption in clinical practice
- The zero hospitalization rate in treated patients over 12 months is exceptional in advanced heart failure care, where readmission rates typically exceed 20% within 30 days
- The validation in JACC, a prestigious peer-reviewed journal, provides strong clinical evidence supporting BVA's utility
From a market perspective, this research could accelerate BVA adoption across healthcare systems by demonstrating clear clinical and economic benefits. Hospitals face significant penalties for heart failure readmissions, making technologies that reduce hospitalizations particularly valuable. The ability to identify and effectively treat this high-risk patient subset could lead to:
- Increased insurance reimbursement opportunities due to demonstrated clinical necessity
- Higher adoption rates in cardiology practices and hospitals
- Expanded use in preventive care settings
The study's implications extend beyond immediate clinical benefits. By identifying a distinct patient phenotype that requires specific treatment, Daxor has effectively created a new diagnostic category that positions its BVA technology as an essential tool in heart failure management. This scientific validation in a major cardiac journal significantly enhances Daxor's competitive moat in the diagnostic space.
Case Reports in the Journal of the American College of Cardiology Underscore the Critical Role of Blood Volume Analysis in Optimizing Heart Failure Treatment
Oak Ridge, TN, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a groundbreaking case series published in JACC: Case Reports has identified a distinct phenotype in heart failure patients characterized by expanded blood volume overload and elevated red blood cells, opening new avenues for targeted treatment through therapeutic phlebotomy. In the study, researchers evaluated 179 advanced heart failure patients using Daxor's blood volume analysis (BVA). Through this analysis, they identified thirty-six patients and closely monitored four heart failure cases over a 12-month period, helping to detect an under-recognized condition.
In the clinical case series, titled, "Identification and Treatment of Hypervolemia and Polycythemia in Patients With Advanced Heart Failure,” researchers discovered that
Key Takeaways:
- BVA detects critical volume issues missed by standard blood tests that drive patient outcomes.
- This condition affects 700,000-1,400,000 US heart failure patients (10
-20% of ambulatory cases). - Patients with this phenotype show worse clinical outcomes than typical heart failure cases.
- Higher stroke and blood clot risks pose additional clinical challenges for these patients if untreated.
- Therapeutic phlebotomy guided by BVA showed significant symptom improvement with zero hospitalizations/deaths over 12 months.
"BVA evaluation is an extremely useful and specific diagnostic test,” said Marc A. Silver, MD, Banner University Medical Center, Advanced Heart Failure, MCS and Heart Transplant, the study's principal investigator. "BVA offers precise, otherwise undetected derangements and insights into the risk of thrombotic events.”
John L. Jefferies, MD, MBA, MPH, Daxor’s Chief Medical Officer, stated, “Optimal volume management is crucial in heart failure care, and these case studies highlight BVA’s unmatched accuracy in identifying patients’ true volume status. By providing precise, individualized guidance, BVA enables clinicians to tailor interventions more effectively, enhancing patient outcomes.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What percentage of heart failure patients showed the new phenotype identified by DXR's blood volume analysis?
How many US heart failure patients could potentially benefit from DXR's blood volume analysis?
What were the clinical outcomes for patients treated with DXR's BVA-guided therapeutic phlebotomy?
What are the risks for heart failure patients with the phenotype identified by DXR's blood volume analysis?
